Basic Information

Gene symbol IL10 Synonyms CSIF, GVHDS, IL-10, IL10A, TGIF Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description interleukin 10

GTO ID GTC2207
Trial ID NCT04124042
Disease Knee Osteoarthritis
Altered gene IL-10
Therapeutic/Target gene Therapeutic gene
TherapyGene transfer
Treatment XT-150
PhasePhase2
Recruitment statusCompleted
TitleA Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee
Year2019
CountryAustralia|United States
Company sponsorXalud Therapeutics, Inc.
Other ID(s)XT-150-2-0204
Vector information
Vectorplasmid

Clinical Result

Cohort1: dose level 1
Administration route intraarticular injection
Dosage Stage A: 0.15 mg/mL XT-150, Stage B: 0.15 mg/mL XT-150
Age Adult, Older_Adult
Cohort2: dose level 2
Administration route intraarticular injection
Dosage Stage A: 0.15 mg/mL XT-150, Stage B: 0.45 mg/mL XT-150
Age Adult, Older_Adult
Cohort3: dose level 3
Administration route intraarticular injection
Dosage Stage A: 0.45 mg/mL XT-150, Stage B: 0.15 mg/mL XT-150
Age Adult, Older_Adult
Cohort4: dose level 4
Administration route intraarticular injection
Dosage Stage A: 0.45 mg/mL XT-150, Stage B: 0.45 mg/mL XT-150
Age Adult, Older_Adult
Cohort5: dose level 5
Administration route intraarticular injection
Dosage Stage A: Placebo, Stage B: 0.15 mg/mL XT-150
Age Adult, Older_Adult
Cohort6: dose level 6
Administration route intraarticular injection
Dosage Stage A: Placebo, Stage B: 0.45 mg/mL XT-150
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph